IRONWOOD PHARMACEUTICALS INC quarterly report, Q2 FY2023

Ironwood Pharmaceuticals, Inc. — Q2 2023 Form 10-Q

Reporting period: Three and six months ended June 30, 2023. Unaudited results are compared with the corresponding 2022 periods. Ironwood is a gastrointestinal-focused company whose principal commercial revenue comes from its LINZESS collaboration with AbbVie.

Financial highlights

Metric	Q2 2023	Six months 2023	Comparable 2022
Revenue	$107.4 million	$211.4 million	$97.2 million and $194.8 million, respectively
Operating income (loss)	$(1,083.1) million	$(1,023.0) million	$55.7 million and $113.5 million, respectively
Net income (loss), consolidated	$(1,089.5) million	$(1,043.8) million	$37.1 million and $75.9 million, respectively
Operating cash flow	$35.0 million	$115.1 million	$61.4 million and $125.5 million, respectively

• Revenue rose 10.4% in Q2 and 8.6% in the first half year over year. Growth primarily reflected higher U.S. LINZESS prescription demand and net price, partly offset by channel inventory fluctuations. U.S. collaboration revenue was $104.8 million in Q2 and $206.4 million for the six months.
• Loss attributable to Ironwood shareholders was $1,062.2 million in Q2 and $1,016.5 million for the first half; diluted loss per share was $6.84 and $6.56, respectively. Results included a $1,090.4 million acquired in-process research and development charge for apraglutide.
• Other Q2 expense increases included $13.0 million of restructuring expense. Research and development was $34.6 million versus $11.5 million; selling, general and administrative expense was $52.5 million versus $30.1 million. Acquisition-related costs and VectivBio equity-award vesting and settlement contributed to the increases.
• Gross margin is not separately reported; the company principally reports collaborative-arrangement revenue reflecting its share of U.S. LINZESS profits and royalties.
• At June 30, cash and cash equivalents were $175.3 million, with total cash, cash equivalents and restricted cash of $176.6 million. Current assets were $317.6 million and current liabilities $305.4 million.
• Total debt principal was $800 million: $400 million of convertible notes due in 2024 and 2026 and $400 million drawn on a secured revolving facility. The revolver has $500 million of total capacity. The balance sheet reports $397.1 million of convertible notes net of issuance costs and $400 million of revolver borrowings. The 2024 notes are classified as current.
• Stockholders’ equity was a deficit of $346.8 million, versus positive equity of $652.4 million at year-end 2022, largely reflecting the acquisition-related charge. The filing does not present a standard operating margin measure.

Material changes and significant events

• Ironwood completed its VectivBio tender offer on June 29, 2023, acquiring 98% of the shares for $17 per share. Total purchase consideration was $1,175.6 million; the company expects to pay about $26.3 million in cash for the remaining shares through a Swiss-law squeeze-out merger.
• The acquisition was accounted for as an asset acquisition, with apraglutide, VectivBio’s lead investigational asset, recorded as acquired IPR&D expense. VectivBio contributed less than 1% of consolidated revenue for the six months, reflecting the very brief post-acquisition consolidation period.
• Cash used in investing activities was $999.5 million, primarily for the acquisition. The company borrowed $400 million under its new secured revolving facility to help fund the transaction.
• Ironwood reduced headquarters-based personnel by about 10% in April and began acquisition-related position eliminations in June. It recorded $13.0 million in restructuring expense and expects another $1–2 million of acquisition-related restructuring expense in the second half of 2023.
• LINZESS received FDA approval in June 2023 for functional constipation in children ages 6–17, making it the first and only FDA-approved prescription treatment for that population, according to the filing.

Outlook, risks and contingencies

• Management said cash on hand at June 30, together with expected operating cash inflows, should fund projected operating needs for at least the next 12 months. This is a forward-looking assessment, not a revenue or earnings forecast; no specific financial guidance was provided.
• Management expects to continue investing in LINZESS and its development pipeline, including apraglutide, IW-3300 and CNP-104. Apraglutide Phase III STARS results for short bowel syndrome with intestinal failure are expected in March 2024; Phase II STARGAZE data for gastrointestinal graft-versus-host disease are expected in Q1 2024. Early CNP-104 patient data are expected in the second half of 2023.
• LINZESS collaboration revenue is a significant source of revenue and depends heavily on U.S. sales and AbbVie’s reporting and settlement. Sales, pricing, rebates, inventory movements and shared commercial costs can affect reported revenue.
• The revolver’s financial covenants begin in Q3 2023 and require a maximum secured net leverage ratio of 3.00:1 and minimum interest coverage of 3.00:1. Ironwood reported covenant compliance at June 30, before those tests began. Borrowings are secured by substantially all personal property; failure to meet covenants or other defaults could restrict liquidity or accelerate obligations.
• Key risks include clinical and regulatory failure or delay, especially for apraglutide; integration and realization of expected benefits from VectivBio; rising indebtedness and debt-service needs; manufacturing and supply issues; competition and intellectual-property disputes; and reliance on collaboration partners. Management excluded VectivBio’s internal controls from its controls assessment while integration proceeds; disclosure controls were assessed as effective at the reasonable-assurance level.
• Ironwood recorded income tax expense of $33.4 million for the first half despite a pretax loss, including effects related to the acquisition and valuation allowances; management expects most of the tax provision to be noncash until net operating losses are used.

Most important facts for investors to verify

• Progress, enrollment, safety and timing of apraglutide’s Phase III and Phase II studies, and whether the expected 2024 readouts remain on track.
• LINZESS U.S. prescription demand, net pricing, channel inventory and AbbVie settlement details behind revenue growth.
• Post-acquisition cash use, integration costs, remaining VectivBio share payments and any further restructuring charges.
• Liquidity and covenant headroom once revolver financial tests begin, interest costs on variable-rate borrowings, and upcoming convertible-note maturities.
• Whether operating cash generation can support planned development and commercial spending while maintaining the stated liquidity outlook.